Vuno Secures $7M Strategic Investment via Perpetual Convertible Bonds

Why It Matters

The funding accelerates Vuno’s entry into regulated European markets, while DUSQ’s capital fuels a novel sleep‑tech offering in the lucrative U.S. market; Samsung’s integration deepens consumer health ecosystems, driving broader digital‑health adoption in emerging economies.

Key Takeaways

• Vuno secures $7M for global AI cardiac product rollout.
• Convertible bonds fund operating capital and EU market entry.
• DUSQ raises $2.6M to launch vagus‑nerve sleep patch in US.
• Samsung Health adds Find Care, linking meds, diagnostics, telehealth.
• Partnerships accelerate digital health adoption in emerging markets.

Pulse Analysis

Vuno’s latest financing underscores the rapid maturation of AI‑enabled medical devices beyond Asia. By issuing perpetual convertible bonds, the company not only secures flexible capital but also signals confidence to European regulators after achieving EU Medical Device Regulation clearance. The recent contracts in Austria and Germany illustrate a strategic push to embed predictive cardiac analytics into hospital workflows, a move that could set a benchmark for AI adoption in acute care settings worldwide.

Meanwhile, DUSQ’s seed round reflects growing investor appetite for neuro‑stimulation wearables that address sleep disorders, a market projected to exceed $100 billion by 2030. The company’s ear‑mounted patch leverages vagus‑nerve stimulation, a clinically validated pathway for improving sleep architecture, differentiating it from conventional tracking devices. By targeting the U.S. market, DUSQ aims to navigate FDA pathways and tap into a consumer base increasingly willing to adopt clinically backed sleep solutions, potentially reshaping the competitive landscape for digital therapeutics.

Samsung Health’s Find Care addition marks a decisive step toward a unified health platform in India, where fragmented services have long hindered seamless patient journeys. By integrating pharmacy, diagnostic, and tele‑consultation capabilities directly into the app, Samsung leverages its massive device ecosystem to drive higher engagement and data capture. The partnership with PharmEasy and Tata 1mg not only expands service reach but also creates cross‑selling opportunities, positioning Samsung as a pivotal orchestrator in the country’s burgeoning digital‑health market.

Deal Summary

South Korean medical AI firm Vuno announced a strategic investment of 10 billion won ($7 million) from the Compass Pathway NXVP New Technology Investment Fund No. 1. The funds will be issued as perpetual convertible bonds and used for operating capital to fuel its global expansion, including its AI‑powered cardiac arrest prediction software.